HALOZYME THERAPEUTICS, INC. (HALO) Operating margin 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) operating margin by fiscal year — reported operating income divided by reported revenue.
33.6%FY2025 · since FY2016: -56.7% → 33.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 33.6% | -20.7 pp |
| FY2024 | 54.3% | +13.6 pp |
| FY2023 | 40.7% | +0.2 pp |
| FY2022 | 40.5% | -21.7 pp |
| FY2021 | 62.2% | +8.3 pp |
| FY2020 | 53.9% | +88.4 pp |
| FY2019 | -34.5% | +11.2 pp |
| FY2018 | -45.7% | -71.2 pp |
| FY2017 | 25.6% | +82.3 pp |
| FY2016 | -56.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →